Abstract：
BACKGROUND: Acting on the main target of dopaminergic cells, the striatal γ-aminobutyric acid (GABA)-ergic cells, might be a new way to treat persons with Parkinson\'s disease (PD).
OBJECTIVE: The objective of this study was to assess the efficacy of bumetanide, an Na-K-Cl cotransporter (NKCC1) inhibitor, to improve motor symptoms in PD.
METHODS: This was a 4-month double-blind, randomized, parallel-group, placebo-controlled trial of 1.75 to 3 mg/day bumetanide as an adjunct to levodopa in 44 participants with PD and motor fluctuations.
RESULTS: Compared to the baseline, the mean change in OFF Movement Disorder Society Unified Parkinson\'s Disease Rating Scale Part III score after 4 months of treatment (primary endpoint) did not improve significantly compared with placebo. No changes between participants treated with bumetanide and those treated with placebo were observed for most other outcome measures. Despite no relevant safety signals, bumetanide was poorly tolerated.
CONCLUSIONS: There was no evidence in this study that bumetanide has efficacy in improving motor symptoms of PD. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
OBJECTIVE: The objective of this study was to assess the efficacy of bumetanide, an Na-K-Cl cotransporter (NKCC1) inhibitor, to improve motor symptoms in PD.
METHODS: This was a 4-month double-blind, randomized, parallel-group, placebo-controlled trial of 1.75 to 3 mg/day bumetanide as an adjunct to levodopa in 44 participants with PD and motor fluctuations.
RESULTS: Compared to the baseline, the mean change in OFF Movement Disorder Society Unified Parkinson\'s Disease Rating Scale Part III score after 4 months of treatment (primary endpoint) did not improve significantly compared with placebo. No changes between participants treated with bumetanide and those treated with placebo were observed for most other outcome measures. Despite no relevant safety signals, bumetanide was poorly tolerated.
CONCLUSIONS: There was no evidence in this study that bumetanide has efficacy in improving motor symptoms of PD. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
摘要：
背景：作用于多巴胺能细胞的主要靶标，纹状体γ-氨基丁酸（GABA）能细胞，可能是治疗帕金森病（PD）患者的一种新方法。
目的：本研究的目的是评估布美他尼的疗效，Na-K-Cl协同转运蛋白（NKCC1）抑制剂，改善PD的运动症状。
方法：这是一个为期4个月的双盲，随机化，平行组，在44名患有PD和运动波动的参与者中，使用1.75至3mg/天的布美他尼作为左旋多巴的辅助药物进行安慰剂对照试验。
结果：与基线相比，与安慰剂相比,治疗4个月后OFF运动障碍协会统一帕金森病评定量表第III部分评分的平均变化(主要终点)没有显著改善.对于大多数其他结果指标，用布美他尼治疗的参与者和用安慰剂治疗的参与者之间没有观察到变化。尽管没有相关的安全信号，布美他尼耐受性差。
结论：本研究中没有证据表明布美他尼对改善PD的运动症状有效。©2024作者由WileyPeriodicalsLLC代表国际帕金森症和运动障碍协会出版的运动障碍。
目的：本研究的目的是评估布美他尼的疗效，Na-K-Cl协同转运蛋白（NKCC1）抑制剂，改善PD的运动症状。
方法：这是一个为期4个月的双盲，随机化，平行组，在44名患有PD和运动波动的参与者中，使用1.75至3mg/天的布美他尼作为左旋多巴的辅助药物进行安慰剂对照试验。
结果：与基线相比，与安慰剂相比,治疗4个月后OFF运动障碍协会统一帕金森病评定量表第III部分评分的平均变化(主要终点)没有显著改善.对于大多数其他结果指标，用布美他尼治疗的参与者和用安慰剂治疗的参与者之间没有观察到变化。尽管没有相关的安全信号，布美他尼耐受性差。
结论：本研究中没有证据表明布美他尼对改善PD的运动症状有效。©2024作者由WileyPeriodicalsLLC代表国际帕金森症和运动障碍协会出版的运动障碍。
